Cencora, Inc. (NYSE:COR) Stock Holdings Decreased by Park National Corp OH

Park National Corp OH lessened its position in Cencora, Inc. (NYSE:COR) by 4.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 39,046 shares of the company’s stock after selling 1,811 shares during the quarter. Park National Corp OH’s holdings in Cencora were worth $8,773,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its holdings in shares of Cencora by 6,855.3% in the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock valued at $464,874,000 after purchasing an additional 2,035,679 shares in the last quarter. Bank of Montreal Can lifted its stake in Cencora by 136.8% in the 2nd quarter. Bank of Montreal Can now owns 641,887 shares of the company’s stock worth $153,623,000 after acquiring an additional 370,841 shares in the last quarter. American Century Companies Inc. boosted its position in Cencora by 155.0% during the 2nd quarter. American Century Companies Inc. now owns 598,438 shares of the company’s stock worth $134,828,000 after acquiring an additional 363,796 shares during the period. Wellington Management Group LLP grew its stake in Cencora by 7.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company’s stock valued at $1,168,927,000 after acquiring an additional 338,452 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of Cencora by 40.2% in the 4th quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company’s stock valued at $243,173,000 after purchasing an additional 308,773 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Up 2.1 %

COR opened at $233.78 on Wednesday. Cencora, Inc. has a twelve month low of $208.58 and a twelve month high of $253.27. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The business has a 50 day moving average price of $237.38 and a 200 day moving average price of $233.51. The firm has a market cap of $45.18 billion, a P/E ratio of 31.13, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a dividend of $0.55 per share. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.94%. The ex-dividend date was Friday, November 15th. Cencora’s dividend payout ratio is currently 29.29%.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares in the company, valued at $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 94,696 shares of company stock worth $22,862,734. 15.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Bank of America reaffirmed a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Wells Fargo & Company dropped their price target on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research note on Friday, December 13th. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective for the company. Evercore ISI boosted their target price on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $275.60.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.